Skip to main content
. 2017 Apr 14;3(2):262–272. doi: 10.1016/j.trci.2017.03.005

Table 2.

Site specificity of anti-Aβ antibody in patients by peptide epitope mapping

Peptide sequence Aβ position Subjects
P101 P102 P103 P104 P105 P106 P107 P108 P109 P201 P202 P203 P204 P205 P206 P207 P208 P209 P210
TEEISEVKMD −9 to 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 EEISEVKMDA −8 to 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 EISEVKMDAE −7 to 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 ISEVKMDAEF −6 to 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 SEVKMDAEFR −5 to 5 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 EVKMDAEFRH −4 to 6 1 0 0 0 0 0 0 0 0 58 0 0 0 0 0 1 0 0 0
 VKMDAEFRHD −3 to 7 31 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 13
 KMDAEFRHDS −2 to 8 94 0 0 0 0 0 0 0 0 2 7 0 12 0 0 0 0 0 52
 MDAEFRHDSG −1 to 9 420 12 0 0 0 0 0 0 0 19 116 0 17 0 0 2 6 0 121
 DAEFRHDSGY 1–10 1983 1669 36 1721 3840 5193 2838 948 1675 1034 42,313 1284 274 81 1797 6024 4093 27,596 20,968
 AEFRHDSGYE 2–11 2 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0
 EFRHDSGYEV 3–12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 FRHDSGYEVH 4–13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 RHDSGYEVHH 5–14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 HDSGYEVHHQ 6–15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 DSGYEVHHQK 7–16 214 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 SGYEVHHQKL 8–17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 GYEVHHQKLV 9–18 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 16 0 0 0
 YEVHHQKLVF 10–19 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 10 0 0 0
 EVHHQKLVFF 11–20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 VHHQKLVFFA 12–21 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 27 0 0 0
 HHQKLVFFAE 13–22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 HQKLVFFAED 14–23 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 QKLVFFAEDV 15–24 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
  DAEFRHDSGYEVHHQKLVFFAEDVGSNK 1–28 685 161 220 295 450 715 1163 478 430 339 509 279 284 39 226 906 1157 893 1321

NOTE. The in vitro anti-Aβ antibody epitope mapping is a competitive binding inhibition enzyme-linked immunoassay for determination of binding residues of anti-Aβ antibody within the target region; the method is described in Section 2. The N-terminal Aβ1–10 (DAEFRHDSGY) peptide (given in bold) was identified to react most strongly with the serum samples collected on week 16 from each of the 19 patients immunized with UB-311; the results show 100% responder rate after immunization at weeks 0, 4, and 12. The numbers represent the dilution factor of each serum sample that corresponds to the 50% binding inhibition (IC50) by each of the 24 Aβ 10-mer peptides.